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Aldh1 Expression and Activity 
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Populations
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Francisco Morís3 & Rene Rodriguez1
Tumors evolve from initial tumorigenic events into increasingly aggressive behaviors in a process 
usually driven by subpopulations of cancer stem cells (CSCs). Mesenchymal stromal/stem cells (MSCs) 
may act as the cell-of-origin for sarcomas, and CSCs that present MSC features have been identified in 
sarcomas due to their ability to grow as self-renewed floating spheres (tumorspheres). Accordingly, we 
previously developed sarcoma models using human MSCs transformed with relevant oncogenic events. 
To study the evolution/emergence of CSC subpopulations during tumor progression, we compared the 
tumorigenic properties of bulk adherent cultures and tumorsphere-forming subpopulations both in the 
sarcoma cell-of-origin models (transformed MSCs) and in their corresponding tumor xenograft-derived 
cells. Tumor formation assays showed that the tumorsphere cultures from xenograft-derived cells, but 
not from the cell-of-origin models, were enriched in CSCs, providing evidence of the emergence of bona 
fide CSCs subpopulations during tumor progression. Relevant CSC-related factors, such as ALDH1 and 
SOX2, were increasingly upregulated in CSCs during tumor progression, and importantly, the increased 
levels and activity of ALDH1 in these subpopulations were associated with enhanced tumorigenicity. In 
addition to being a CSC marker, our findings indicate that ALDH1 could also be useful for tracking the 
malignant potential of CSC subpopulations during sarcoma evolution.
Tumors initiate from a permissible cell-of-origin that receives the first oncogenic events needed to trigger tumoral 
proliferation1,2. According to the hierarchical model of cancer, after this initial step, tumors gain complexity and 
cellular heterogeneity, among other factors, through the emergence of tumor-propagating subpopulations or 
CSCs, which exhibit stem cells properties and are responsible for sustaining tumorigenesis3,4. Therefore, the evo-
lution of these subpopulations through gaining new genetic and/or epigenetic alterations drives the evolution of 
tumors toward enhanced aggressiveness5.
Sarcomas comprise a heterogeneous group of aggressive mesenchymal malignancies that often show a limited 
clinical response to current therapies6. Experimental evidence supports the notion that many types of sarcomas 
are hierarchically organized and sustained by subpopulations of self-renewing CSCs that can generate the full 
repertoire of tumor cells and display tumor re-initiating properties7,8. In addition, it has been recently established 
that transformed MSCs and/or their immediate lineage progenitors are the most likely cell-of-origin for many 
types of sarcomas8–10. Accordingly, many of the CSC sub-populations identified in different types of sarcomas 
displayed MSC phenotype and functional properties7,8,11–13. Therefore, many efforts have been made to produce 
models of sarcomas based on MSCs transformed with relevant oncogenic events8,10. These types of models rep-
resent unparalleled systems for unraveling the mechanisms underlying sarcomagenesis from the cell-of-origin, 
exploring the evolution of CSC subpopulations and designing specific therapies that are able to target the tumor 
populations that initiate, sustain and expand the tumor.
Several methods have been developed to isolate subpopulations with stem cell properties within tumors14,15. 
Among these methods, the ability of certain cell subsets to grow as self-renewing tumorspheres under 
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nonadherent and serum-starved culture conditions (sphere-formation assay) were first used to identify tissue 
stem cells16 and later CSCs from many type of tumors including sarcomas7,14,17–19. In addition, members of the 
aldehyde dehydrogenase family (ALDH) are upregulated in multipotent cells and have been proposed as potential 
universal markers for the identification of stem cells and CSCs from multiple sources20,21. ALDH is an enzyme 
responsible for oxidizing endogenous and exogenous aldehydes into their corresponding carboxylic acids22. 
Accordingly, this family of enzymes plays a self-protective, detoxifying role and therefore seems to influence the 
chemotherapy resistance observed in CSC subpopulations23. Other important functional roles of ALDH family 
members include participation in the retinoid signaling pathway and regulation of the expansion and differenti-
ation of SC and CSCs21. Importantly, high expression and activity of members of the ALDH1 subgroup has been 
associated with poor prognosis and metastatic potential in several types of cancer21,24,25. In order to effectively 
use ALDH1 as a CSC marker, a method known as ALDEFLUOR assay was developed to sort cells based on their 
ALDH1 activity26. Consequently, the ALDEFLUOR assay has been widely used to isolate CSC subpopulations in 
various tumors including different types of sarcomas23,27–31. These CSC subpopulations commonly overexpress 
pluripotency factors such as Sex-determining region Y-Box2 (SOX2), which plays important roles in the regulation 
of self-renewal and tumorigenicity in CSC subpopulations of several types of cancer32–37.
The process of emergence/evolution of CSC subpopulations from the cell-of-origin in sarcomagenesis has 
barely been addressed. In this report, we used our previously developed cell-of-origin-based models of sarcoma 
(Table S1)38–40 to analyze the evolution of CSC subpopulations during tumor progression. We found that the 
increase in the malignant potential of tumorsphere-forming subpopulations is associated with enhanced expres-
sion of SOX2 and the ALDH1 isoforms ALDH1A1 and ALDH1A3. Furthermore, ALDH1 activity correlates with 
tumorigenic potential during tumor progression, suggesting that this CSC marker could serve to monitor the 
malignant potential of CSC subpopulations during the course of the disease.
Results
Self-renew and differentiation properties of transformed hMSCs and their derived tumor cell 
lines. We have previously developed and characterized sarcoma models using human bone marrow MSCs 
(BM-MSCs) sequentially mutated with up to 6 oncogenic events [(1) hTERT overexpression; (2 & 3) P53 and Rb 
inactivation using E6 and E7 antigens of the HPV-16; (4) inactivation of PPA2 phosphatase with SV40 small T 
antigen (4 hits combination; MSC-4H); (5) expression of oncogenic H-RASv−12 (5 hits combination; MSC-5H); 
and (6) the expression of FUS-CHOP (FC)] (Table S1)38–40. Three of the resulting cell lines were fully transformed 
and able to initiate sarcomas in vivo. Thus, GFP-expressing MSC-5H (MSC-5H-GFP) cells give rise to spindle cell 
sarcomas (SCS); meanwhile, FUS-CHOP-expressing hMSCs (MSC-4H-FC and MSC-5H-FC) originate myxoid/
round cell liposarcomas (MRCLS).
We first study how sphere-formation ability evolves during tumor evolution by comparing data obtained 
from these cell-of-origin models with data obtained from several xenograft-derived cell lines that are able to 
recapitulate the originally formed sarcoma (T-4H-FC#1, T-5H-GFP#1 and T-5H-FC#1)38,40 (Fig. 1A; Table S1). 
All cell-of-origin models [MSC-4H and MSC-5H cell types (MSC-XH)] and tumor cell lines [T-4H and T-5H 
cell types (T-XH)] can be serially expanded as self-renewed spheres with similar efficiency (Fig. 1B), although 
T-XH-derived spheres were much larger than those formed by MSC-XH cells (Fig. 1C and Figure S1). By per-
forming time-lapse microscopy, we could monitor the sphere-formation process. Interestingly, we observed clonal 
division of T-5H-FC#1 cells combined with aggregation of forming spheres into bigger clusters (Fig. 1D; Figure 
S2; Video S1; Video S2). Similarly, in MSC-5H-FC cells, we observed both clonal tumorsphere formation (Fig. 1E; 
Figure S3A; Video S3) and aggregation in the initial steps of the tumorsphere-formation process (Figure S3B; 
Video S3). These data indicate that aggregation occurs in low density multi-cell sphere cultures even when media 
is supplemented with methylcellulose to reduce the mobility of the cells. In any case, a high percentage of spheres 
were initiated by the clonal division of a single cell and not by the aggregation of two or more cells (Video S1; 
Video S2; Video S3).
To further confirm the existence of cells that are able to form clonal spheres in these sarcoma models and to 
estimate their frequency, we performed limiting dilution assays (LDA) to detect tumorsphere formation from 
1000, 100, 10 and 1 cell (Fig. 1E). Single-cell assays showed that a high percentage of cells (between 23.0% and 
37.9%) were indeed able to initiate clonal growth. Sphere-forming frequency (SFF) calculated using ELDA soft-
ware was also notably high in all cell types.
CSC subpopulations isolated from sarcomas have been reported to exhibit differentiation potential to MSC 
related lineages7,12,41. We previously found that this collection of sequentially mutated MSCs lost their adipogenic 
potential during the transformation process, and MSC-4H, MSC-5H, T-5H and T-4H cells (regardless the expres-
sion of FUS-CHOP) displayed an impaired pattern of differentiation in which most cells of the culture presented 
a small amount of lipid droplets in their cytoplasm. In addition, MSC-4H and MSC-5H cells retained their full 
ability to differentiate toward the osteogenic lineage40. We found that tumorspheres derived from all cell types 
display high osteogenic and low adipogenic potential similar to that observed in the corresponding bulk adherent 
cultures (Figure S4). Given that the blockage of the adipogenic differentiation pathways is a hallmark of liposar-
coma development42, this finding is in line with a liposarcoma-forming potential of these cells when combined 
with other liposarcoma instructive mutations such as the expression of FUS-CHOP.
Tumorsphere cultures from tumor-derived cells but not from the cells of origin are highly 
enriched in CSCs. Transplantation assays into immunocompromised mice is the current “gold standard” for 
identifying CSCs1. To check whether tumorsphere cultures of both a cell-of-origin model and their derived cell 
lines are enriched in tumor-initiating cells able to reproduce the original tumor, we inoculated cells from both 
adherent and tumorsphere cultures into NOD-SCID mice. We found that the sphere-forming subpopulation 
of T5H-FC#1 cells more efficiently induces tumor formation in immunodeficient mice than the bulk adherent 
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cultures. Thus, significant differences in tumor growth were observed as early as 12 days after cell inoculation, 
and a 5-fold difference in tumor volume was evidenced at day 22 (Fig. 2A,B). Otherwise, MSC-5H-FC-formed 
spheres need a much larger latency period to induce tumor formation, and adherent cultures showed only a 
slight and nonsignificant delay in tumor formation when compared with the corresponding tumorsphere cultures 
(Fig. 2A,B). Importantly, tumorsphere cultures of both MSC-5H-FC and T-5H-FC#1 cells were able to reproduce 
all the features of the human MRCLS (Fig. 2C), confirming that i) MSC-5H-FC cells act as cell-of-origin for this 
type of tumor as we previously shown40, and ii) T-5H-FC#1 cultures contain CSCs that are able to reproduce all 
the heterogeneity of the original tumor.
To confirm and quantify the enrichment of CSCs in the tumorsphere cultures of T5H-FC#1 cells, we per-
formed LDA assays comparing adherent and tumorsphere cultures. As shown above, tumorsphere cultures pro-
duce a significantly faster tumor growth than adherent cultures at all the assayed cell dilutions (Fig. 2D). Given 
that adherent cultures also contain CSCs, tumor formation were eventually observed in all cases. Therefore, we 
used data from the day when the tumorsphere and adherent series start to show significant differences (day 14) 
Figure 1. MSC-XH and T-XH cells can be serially expanded as self-renewing spheres. (A) The evolution 
of CSC subpopulations was studied by comparing the tumorsphere-forming subpopulations derived from 
MSC-XH cells (cell-of-origin models) versus those derived from their corresponding tumor xenograft-derived 
T-XH cells, which represent a model of malignant tumor progression. (B–C) Serial tumorsphere formation 
ability of MSC-XH and T-XH cells. Number (B) and representative images (C) of tumorspheres formed in 
each passage. (D–E) Monitoring of the the sphere formation process in T-5H-FC#1 (D) and MSC-5H-FC (E) 
cells by time-lapse microscopy (see also Figures S1 and S2 and Videos S1, S2 and S3). Each image is in panel 
D composed by two adjacent pictures automatically taken and merged by the imaging system. (E) Limiting 
dilution assay of the tumorsphere formation ability of the indicated cell lines. The number of wells presenting 
tumorspheres and total number of wells assayed in each condition is indicated (n). SFF was calculated using 
ELDA software, Pr (>chiSq) values referring to MSC-XH cells are indicated.
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to perform ELDA analysis to identify CSCs in adherent and tumorsphere cultures. On this day, the inoculation 
of 5 × 105 cells initiated tumor formation in all cases; the inoculation of 5 × 104 cells produced tumors in all 
mice inoculated with tumorspheres, but only 2 out of 6 mice inoculated with adherent culture cells; and the 
inoculation of 1 × 104 cells generated tumors in 5 out of 6 mice inoculated with of tumorspheres and no tumor 
Figure 2. Tumor formation ability of tumorsphere cultures from MSC-5H-FC and T-5H-FC#1 cells. (A) 
Tumor growth kinetics observed after the inoculation into immunodeficient mice of 1 × 104 cells from adherent 
or tumorsphere cultures of MSC-5H-FC and T5H-FC#1 cells. (B) Representative images of tumors at the 
experimental endpoint. (C) Tumor formed by both MSC-5H-FC and T5H-FC#1 cultures form tumors (left 
and middle panels) and lung metastasis (right panels) displaying the main characteristics of human MRCLS: 
myxoid matrix (M), round-cell areas (R), lipoblasts (blue arrows) and plexiform vascular pattern (red arrows). 
(D) Tumor growth kinetics observed after the inoculation into immunodeficient mice of the indicated number 
of cells of adherent or tumorsphere cultures of T5H-FC#1 cells. (E) Limiting dilution assay to evaluate tumor 
re-initiation ability of adherent and tumorsphere cultures of T-5H-FC#1 cells. The number of mice that grew 
tumors at day 14 and total number of inoculated mice for each condition is indicated. TIF was calculated using 
ELDA software. Error bars represent the standard deviation and asterisks indicate a statistically significant 
difference between the tumorspheres and adherent cell conditions (* p < 0.05, * * p < 0.001; two-sided Student’s 
t-test). In limiting dilutions assays Pr (>chiSq) value is indicated.
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formation was detected in the case of adherent cultures. Therefore, an ELDA analysis showed a 22-fold enrich-
ment in tumor-initiating frequency (TIF) in tumorsphere cultures (1 in 5572) versus adherent cultures (1 in 
125186) (Fig. 2E). These experiments suggest that tumorsphere cultures from the T-5H-FC#1 sarcoma-derived 
cell line are highly enriched in CSCs. On the other hand, their cell-of-origin cell line (MSC-5H-FC), although able 
to grow as floating spheres (most likely due to their intrinsic properties and not only by their tumorigenic status), 
could not be significantly enriched in subpopulations with increased tumorigenicity by tumorsphere culture.
Different regulation of CSC-related factors in tumorsphere cultures of cells of origin and 
tumor-derived cells. To gain insight about the different abilities of tumorsphere cultures from the 
cell-of-origin model and the sarcoma-derived cell lines to enrich tumor re-initiating subpopulations, we per-
formed RT-PCR in MSC-5H-FC and T-5H-FC#1 cells to analyze the expression of an array of 84 genes with 
well-known functions in pluripotency, self-renewal, migration, metastasis and signal transduction in CSCs as well 
as CSC markers. When compared to adherent cultures, tumorsphere cultures of MSC-5H-FC and T-5H-FC#1 
cells showed altered expression (fold change ≥ 2) of 32 and 27 genes, respectively, although many more changes 
reach statistical significance (p < 0.05) in T-5H-FC#1 (16) than in MSC-5H-FC (5) (Fig. 3A,B). Differently upreg-
ulated genes in MSC-5H-FC cells include several pluripotency factors such as KLF4, LIN28A or POU5F1/OCT4, 
and CSC markers such as KIT and MUC1. Meanwhile, T-5H-FC#1 displayed a remarkable upregulation of two 
well-known CSC-promoting factors such as ALDH1A1 and SOX220,34,35 (Fig. 3A,B). Consistently, ALDH1A1 (fold 
regulation: 22.02) and SOX2 (38.88) were expressed in T-5H-FC#1-derived tumorspheres at higher levels than 
in those formed by MSC-5H-FC cells (Fig. 3C). Other CSC markers and signaling molecules that were upregu-
lated in T-5H-FC#1 tumorspheres included Dickkopf-1 (DKK1), LIN28A, ITGA2, ITGA6, ALCAM, MERTK and 
NOTCH1. Meanwhile, SMO, THY1/CD90 and KLF17 were downregulated (Fig. 3C).
Increased expression of SOX2 and ALDH1 in CSC subpopulations during tumor progression. 
According to gene expression experiments, a western blotting analysis confirmed that SOX2 and ALDH1A1 
protein levels were upregulated in T-5H-FC#1 tumorspheres at a greater level than in MSC-5H-FC tumor-
spheres (Fig. 4A). Moreover, the immunofluorescence analysis of adherent cultures and tumorspheres that were 
allowed to attach to the substrate before fixation showed that T-5H-FC#1 adherent and tumorsphere cultures 
presented a significantly higher percentage of SOX2-positive stained nuclei than the respective nuclei of MSC-
5H-FC cultures, with the nuclei of T-5H-FC#1 tumorspheres displaying the higher levels (Fig. 4B,C). Similar 
results were obtained after an immunofluorescence analysis of ALDH1A1 expression (cytosolic + nuclear) 
(Fig. 4D,E). Furthermore, in situ simultaneous immunofluorescent staining of SOX2 and ALDHA1 confirmed 
that T-5H-FC#1 tumorspheres displayed a higher proportion of cells presenting nuclear expression of SOX2 and 
a higher expression of cytosolic ALDH1A1 compared with MSC-5H-FC tumorspheres (Fig. 4F). Nevertheless, 
both populations are not totally overlapping, and there are subsets of cells expressing high levels of nuclear SOX2 
but not high ALDH1A1 (Fig. 4F, blue arrows) and vice versa (white arrows).
To correlate the increased expression of ALDH1 with its enzymatic activity, we performed an ALDEFLUOR 
assay with adherent and tumorsphere cultures. Because this assay is based on the generation of a green fluorescent 
compound, we used the original MSC-5H cells (MSC-5H-O) and a cell line derived from a MSC-5H-O-generated 
xenograft (T-5H-O), neither transduced with GFP-expressing lentiviral vectors. We first checked the protein lev-
els of ALDH1A1 and ALDH1A3, another ALDH1 isoform that has been reported to contribute to ALDEFLUOR 
activity43. These two isoforms were upregulated at greater levels in T-5H-O tumorspheres than in MSC-5H-O 
tumorspheres (Fig. 4G), as was seen when comparing MSC-5H-FC and T-5H-FC#1 cells. Similarly, the 
ALDEFLUOR assay showed that T-5H-O cells displayed higher levels of activity than MSC-5H-O cells in both 
adherent and especially tumorsphere cultures (Fig. 4H,I).
To study the contributions of ALDH1A1 and ALDH1A3 to the ALDEFLUOR activity, we performed siRNA 
knockdown of both isoforms in T-5H-O cells. Western blotting confirmed similar knockdown efficiency of both 
proteins (Fig. 5A). ALDEFLUOR assays showed that ALDH1A1 and ALDH1A3 depletion inhibited the activity 
by 30% and 70%, respectively, indicating that both isoforms contribute to the ALDEFLUOR activity, although 
ALDH1A3 seems to be the largest contributor (Fig. 5B,C).
Altogether, these results show that SOX2, ALDH1A1 and ALDH1A3 expression, together with their asso-
ciated ALDEFLUOR activities are progressively enhanced in CSC subpopulations during sarcoma progression 
toward more aggressive phenotypes.
ALDH1high cells displayed increased tumorigenic properties. To determine whether the cells pre-
senting high ALDH1 activity are also enriched with tumor-propagating properties, we used the ALDEFLUOR 
assay to isolate ALDH1high and ALDH1low by flow cytometry (Fig. 6A). As expected, the ALDH1high fraction of 
T-5H-O cells retained most of the expression of ALDH1A1 and ALDH1A3 proteins. Likewise, SOX2 expression 
was highly increased in the ALDH1high fraction (Fig. 6B). Similar results were observed after the analysis of 
ALDH1high and ALDH1low populations in MSC-5H-O cells (Figure S5A). On the other hand, KLF4, which was 
upregulated in tumorsphere cultures of MSC-5H-FC cells, was not enriched in ALDHhigh sorted populations of 
MSC-5H-O or T-5H-O cells (Figure S5B), similar to previous observations in osteosarcoma samples44.
Notably, the ALDH1high fraction in T-5H-O cells presented a higher ability to form colonies in soft agar, a sur-
rogate in vitro transformation assay (Fig. 6C). In contrast, ALDH1high and ALDH1low populations showed similar 
abilities to form serially passaged tumorspheres (results from two separate experiments shown in Fig. 6D and 
Figure S6A). To further analyze the self-renewal and tumorigenic properties of both populations, second-passage 
tumorsphere cultures from ALDH1high and ALDH1low cells were disaggregated and assayed form colony forma-
tion in soft agar. Again, ALDH1high cells displayed enhanced cell growth in these conditions (Fig. 6E and Figure 
S6B). Moreover, the ALDEFLUOR assay performed with the cells recovered from the in vitro transformation 
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assay reveled that ALDH1high cells maintain high levels of ALDH1 activity while the ALDH1low cells were moder-
ately enriched in ALDH1 activity after tumorsphere culture (Fig. 6F and Figure S6C).
Finally, we found that as few as 400 ALDH1high cells were sufficient to develop tumors in vivo with 100% of 
incidence (n = 6). The immunohistological analysis showed that these tumors resembled the original SCS histol-
ogy and that only a small portion of tumor cells (< 5%) expressed high levels of ALDH1A1 (Fig. 6G). These results 
indicate that high activity of ALDH1 is strongly related to increased tumorigenic properties and that ALDH1high 
cells behave as true CSC subpopulations able to regenerate all the tumor cell subpopulations.
Figure 3. Different regulation of CSC-related factors in tumorsphere cultures of MSC-5H-FC and 
T-5H-FC#1 cells. RNA obtained from adherent and tumorspheres cultures of the indicated cell lines were used 
to analyzed the expression of 86 CSC-related genes (RT2 Profiler™ PCR Array System PAHS-176Z, Qiagen). 
(A–C) Upper panels show the scatter Plots representing the expression level of each gene in MSC-5H-FC 
spheres versus MSC-5H-FC adherent cultures (A), T5H-FC#1 spheres versus T-5H-FC#1 adherent cultures 
(B) and T5H-FC#1 spheres versus MSC-5H-FC spheres (C). Genes above and below the dark-red lines are 
expressed more than two fold up or down in test versus control samples. Bottom panels display the list of 
genes with fold change ≤ − 2 or ≥ 2 for each comparison. Genes showing statistically significant differences 
(p-value ≤ 0.05, two sided Student’s t-test) are depicted in bold.
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Figure 4. Increased expression of SOX2 and ALDH1 in CSC subpopulations during tumor progression. 
(A) Protein levels of ALDH1A1 and SOX2 in adherent (A) and tumorsphere (T) cultures of MSC-5H-FC and 
T5H-FC#1. β -actin levels were used as loading control. (B,D) Immunofluorescence staining of SOX2 (B) and 
ALDH1A1 (D) in adherent cultures or tumorsphere disaggregates and allowed to attach to glass slides of MSC-
5H-FC and T5H-FC#1 cells. Scale bars = 50 μ m (B) or = 40 μ m (D). (C,E) Quantification of nuclear SOX2 
(C) or cytosolic and nuclear ALDH1A1 (E) staining in each sample. (F) Simultaneous immunofluorescence 
staining of SOX2 and ALDH1A1 in GFP-expressing MSC-5H-FC- and T5H-FC#1-derived tumorspheres. Scale 
bars = 200 μ m. (G) Protein levels of ALDH1A1, ALDH1A3 and β -actin in adherent (A) and tumorsphere (T) 
cultures of the indicated cell types. (H,I) ALDEFLUOR assay showing the activity of ALDH1 in adherents and 
tumorspheres cultures of MSC-5H and T5H-O cells. ALDH1 activity was blocked with the specific inhibitor 
DEAB to establish the basal level. The summary of 3 independent experiments (I) and a representative assay 
(H) is presented. Error bars represent the standard deviation and asterisks indicate a statistically significant 
difference between the indicated conditions (* p < 0.05, * * p < 0.001; two-sided Student’s t-test).
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Discussion
To gain insights about the evolution of CSC subpopulations during tumor progression in sarcomas, we compared 
the tumorsphere-forming subpopulations derived from MSC-XH cells (cell-of-origin models) vs. those derived 
from their corresponding tumor xenograft-derived T-XH cells (Fig. 1A)38,40. We observed that both MSC-XH 
and T-XH cells formed clonal tumorspheres with very high efficiency. In this regard, it is likely that the intrinsic 
self-renewal properties of the MSCs45,46 acting as cell-of-origin for sarcomas could result in higher frequencies of 
tumorsphere formation upon tumoral transformation. In fact, high frequencies of tumorsphere formation have 
previously been reported in some cases of sarcoma12. Notably, certain cautions have been raised about the use of 
tumorsphere cultures to enrich CSC subpopulations in some cases. Thus, using imaging approaches, neurospheres 
were observed to frequently aggregate even at low densities47. Similarly, using time-lapse microscopy, we showed 
that in low-density multi-cell tumorsphere cultures, aggregation occurs even in the presence of methylcellulose. 
In any case, our experiments also demonstrate that clonal proliferation takes place before and after sphere aggre-
gation both in MSC-5H-FC and T-5H-FC#1 cells. Importantly, we found remarkable differences in the ability of 
these clonal/aggregated tumorsphere cultures from these two cell types to effectively enrich in tumor-initiating 
populations (Table 1). On the one hand, tumorsphere cultures from the T-5H-FC#1 sarcoma-derived cell line are 
highly enriched in CSCs as seen by their highly increased capacity to initiate tumor formation in vivo. On the 
Figure 5. Depletion of ALDH1 isoforms result in reduced ALDEFLUOR activity. (A) Protein levels of 
ALDH1A1 and ALDH1A3 48 h after the transfection of the indicated siRNAs in T-5H-O cells. β -Actin levels 
are presented as a loading control. (B,C) ALDEFLUOR assay of T-5H-O cells depleted for ALDH1A1 or 
ALDH1A3. The percentage of reduction achieved by each ALDH1 isoform depletion respect to the control 
siRNA values (n = 3 independent experiments) (B) and a representative assay (C) is presented.
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other hand, their cell-of-origin cell line (MSC-5H-FC), although able to grow as floating spheres, could not be 
significantly enriched in subpopulations with increased tumorigenicity by tumorsphere culture. Altogether, this 
model of sarcomagenesis evolution suggests the differences between a non-heterogeneous cell-of-origin popu-
lation able to initiate sarcomagenesis (MSC-5H-FC cells) and the increasingly aggressive CSC subpopulations 
that emerge during in vivo tumor progression (T-5H-FC#1 cells). These tumor-propagating subpopulations most 
likely appear and evolve through the accumulation of epigenetic alterations and are a source of intra-tumor het-
erogeneity1. These results also reflect the importance of performing in vivo tumor-formation experiments to 
confirm the ability of tumorsphere cultures to enrich in bona fide CSC subpopulations.
Figure 6. ALDH1high cells displayed increased tumorogenic properties. (A) Flow cytometry cell sorting of 
ALDEFLUOR high (ALDH1high) and low (ALDH1low) populations in T-5H-O cells. (B) Protein levels of the 
indicated factors in sorted populations. β -actin levels were used as loading control. (C) Relative quantification 
of the soft agar colony formation (anchorage independent growth) ability of ALDH1high and ALDH1low 
populations. Representative images of colonies are shown (top panels). (D–F) Sorted cells were growth as 
tumorspheres for two successive passages (D), disaggregated and assayed for soft agar colony formation (E) and 
finally, recovered from soft agar cultures and assayed for ALDEFLUOR activity (F). (G) H&E (left panel) and 
ALDH1A1 immunostaining (right panel) of tumors arising in mice inoculated with 400 ALDH1high cells. Scale 
bars = 500 μ m in panels (C–E) and = 200 μ m (100 μ m for right panel inset) in panel G. Error bars represent the 
standard deviation and asterisks indicate a statistically significant difference between the indicated conditions  
(* p < 0.05, * * p < 0.001; two-sided Student’s t-test).
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By analyzing the expression of several genes involved in the CSC phenotype in MSC-5H-FC and T-5H-FC#1 
adherent and tumorsphere cultures, we found a group of genes highly enriched in T-5H-FC#1 vs. MSC-5H-FC 
tumorsphere cultures that are therefore progressively increased in tumorsphere-forming subpopulations during 
sarcoma progression. Among these genes, ALDH1A1 and SOX2 were the most highly upregulated in T-5H-FC#1 
tumorspheres and may be meaningful indicators of CSC progression in sarcomagenesis and also useful for the 
prospective isolation of CSCs. Both factors were also upregulated at protein levels and their ALDEFLUOR activ-
ities were equally enhanced in T-5H vs. MSC-5H tumorspheres (Table 1). In line with this finding, the upregu-
lation of the mRNA levels of ALDH1A123 and SOX212,18,19,23 were already detected in tumorsphere cultures of 
sarcomas.
It is important to note that apart from ALDH1A1, other members of the ALDH superfamily, especially 
ALDH1A3, seem to contribute to ALDEFLUOR activity43,48. We confirmed that, similar to ALDH1A1, ALDH1A3 
was upregulated in tumorsphere cultures. Likewise, cells with high ALDEFLUOR activity retain most of the 
ALDH1A1 and ALDH1A3 expression, and both isoforms contribute importantly to ALDEFLUOR activity in our 
models. In any case, we could not discard a potential role for other members of the ALDH family.
ALDH1 activity has been used to isolate CSC subpopulations in different types of sarcomas23,27–31. These stud-
ies found that subpopulations with high activity of ALDH1 showed increased expression of pluripotency markers 
like SOX2, enhanced ability to grow as tumorspheres, increased tumorigenicity and strong chemo-resistance. In 
line with these findings, we found that SOX2 expression was highly increased in ALDH1high cells. However, we 
observed that both ALDH1high and ALDH1low populations are able to grow as tumorspheres, indicating that other 
markers or combinations of markers are needed to discriminate tumorsphere-forming populations. In any case, 
ALDH1 activity was always enriched in these growth conditions and ALDH1high cells possess high self-renewal 
potential as indicated by their ability to grow as serially passaged spheres that maintain high ALDH1 activity. 
Importantly, we also found that ALDH1 activity in T-5H cells was associated with enhanced tumorigenic proper-
ties. Therefore, our findings correspond to previous studies suggesting that ALDH1 seems to constitute a valuable 
CSC marker in sarcomas. Moreover, we present for the first time evidence that ALDH1 expression and activity is 
increased during tumor evolution in CSC subpopulations (T-5H vs. MSC-5H tumorsphere cultures), suggesting 
that the level of ALDH1 could be used as an indicator of the evolution of the CSCs’ malignant potential.
Similar to ALDH1, our results show that SOX2 is upregulated in CSC subpopulations during tumor evolution. 
Importantly, the depletion of SOX2 has been reported to induce a significant decrease in the tumor-initiating 
capability of ALDH1high cells in melanoma37. We found that SOX2 was highly enriched in ALDHhigh populations, 
although certain level of SOX2 expression was detected in ALDHlow cells. In addition, immunofluorescence anal-
ysis of tumorspheres that are enriched in ALDEFLUOR activity showed cells expressing different levels of SOX2. 
Altogether, these data suggest that the selection of SOX2+/ALDHhigh cells could result in a better discrimination 
of CSC subpopulations. As commented before, live cells with high ALDH1 activity can be easily sorted using the 
ALDEFLUOR assay. Unfortunately, the sorting of live cells based on the level of SOX2 expression cannot yet be 
achieved despite some promising technical advances49. Once this technology becomes available, it would be able 
to separate subpopulations presenting high activity or expression of both ALDH1 and SOX2 and could potentially 
represent tumor-propagating subpopulations better than the cell subset solely selected by ALDH1 activity.
Beside ALDH1A1 and SOX2, other molecules such as DKK1 and NOTCH1 were notably upregulated in CSCs 
during tumor progression. Notably, the WNT-antagonist DKK1 has been proposed to enhance pro-tumorigenic 
properties in osteosarcoma, in part through the upregulation of ALDH1A150. Likewise, NOTCH signaling has 
been associated with ALDH activity and increased metastatic potential in osteosarcoma cells51.
In conclusion, our model of sarcomagenesis initiated from transformed BM-MSCs, allowing us to study the 
evolution of the tumor from the cell-of-origin toward increasingly aggressive xenograft-derived cells. By com-
paring the tumorigenic properties of the tumorsphere-forming populations derived from both populations, we 
evidenced the emergence of bona fide CSC subpopulations during tumor progression. Several factors related 
with the CSC phenotype, such as ALDH1A1, SOX2, DKK1 and NOTCH1, were increasingly upregulated in the 
emerging CSC subpopulations during tumor progression. Importantly, the increased levels of ALDH1 expression 
and activity in these subpopulations was associated with enhanced tumorigenicity, thus confirming the suitability 
Cell of origin model 
(MSC-5H)
model of tumor 
evolution (T-5H)
intra-tumor heterogeneity low increased
sphere forming ability* + + + (small spheres) + + + (large spheres)
selection of tumor initiating cells by tumorsphere culture* + + + + 
increase of ALDH1A1 in tumorspheres* + + + + 
increase of ALDH1A3 in tumorspheres* + + + + 
levels of ALDEFLUOR activity* + + + + + 
increase of SOX2 in tumorspheres* + + + + 
increase in sphere forming ability in ALDHhigh cells* n.a. − 
increase of tumorigenic properties in ALDHhigh cells* n.a + + 
Table 1.  Main differences observed between the cell-of-origin models and their derived tumor xenograft 
cell lines. (* ) Relative level of increase in the indicated properties: (−): no differences; (+): small increase; (+ +): 
moderate increase; (+ + +): large increase; n.a.: not analyzed.
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of this molecule to be used as a CSC marker for sarcomas and also suggesting that ALDH1 could be useful for 
tracking the malignant potential of CSC subpopulations during tumor evolution and treatment.
Methods
Cell types. Human BM-MSCs sequentially mutated with up to 6 oncogenic events, and tumor lines derived 
from transformed BM-MSC-induced xenografts were previously generated and characterized (Table S1)38–40. The 
identity of transformed human BM-MSCs has been authenticated by a Short Tandem Repeats analysis during the 
last 5 months. All the cell types were cultured as previously described40,52. All experimental protocols have been 
performed in accordance with institutional review board guidelines and were approved by the Institutional Ethics 
Committee of the Hospital Universitario Central de Asturias. All samples from human origin were obtained upon 
signed informed consent.
Tumorsphere culture. Cells lines were plated at a density of 5,000 cells per well in 6-well plates (2.5 cell/μ l) 
treated with a sterile solution of poly 2-hydroxyethyl methacrylate (10 g/l in 95% ethanol; Sigma) to prevent 
cell attachment, in serum-free sphere medium containing DMEM-F12 (GE Healthcare, Pittsburg, PA) supple-
mented with Glutamax (1:100; Life Technologies, Carlsbad, CA), B-27 Supplement (1:50; Life Technologies), 
Heparin (1:1000; Sigma, St Louis, MO), the growth factors human EGF (20 ng/ml) and human bFGF (10 ng/ml; 
PeproTech, London, UK) and 1% methylcellulose (Sigma) to avoid cell aggregation. In addition, fresh aliquots of 
EGF and bFGF were added every three days. After 10–12 days, well-formed spheres were filtered through 70-μ m 
cell strainers (Corning, New York, NY), washed with phosphate-buffered saline and disaggregated by incubation 
with trypsin (0.25%)/EDTA (Life Technologies) for 15 min. The resulting cell suspension was pelleted, counted 
and replated as before to continue serially passaged tumorsphere cultures. In LDA, serially diluted numbers of 
cells (from 1000 to 1 cell) were plated in poly 2-hydroxyethyl methacrylate-treated 96-well plates and cultured 
as explained above. Presented data are aggregates of two independent experiments (Supplemental Material). 
After 10 days, the number of wells presenting spheres were counted and the sphere-forming frequency (SFF) 
was calculated using the ELDA software53. Tumorsphere formation was monitored using a Zeiss Cell Observer 
Live Imaging microscope (Zeiss, Thornwood, NY) coupled with a CO2 and temperature-maintenance system. 
Time-lapse images were acquired every 8 hours during 6 days using a Zeiss AxioCam MRc camera.
Analysis of CSC-related genes using RT-PCR arrays. The Human Cancer Stem Cells RT2 Profiler PCR 
Array (PAHS-176-Z; SABiosciences, Qiagen Iberia, Madrid, Spain) was used to analyze the expression of 84 
genes linked to CSCs properties according to the manufacturer instructions. Only RNA samples with RNA integ-
rity ≥ 9 were used in the analysis as determined using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA). The RT-qPCR reactions were performed for three independent experiments of each condition in a 
StepOnePlus Real Time PCR system (Life Technologies, Carlsbad, CA) using the RT2 First Strand Kit and the 
RT2 qPCR SYBR Green/ROX MasterMix (SABiosciences). The PCR conditions included an initial denaturation 
step at 95 °C for 10 minutes, followed by 40 cycles of a denaturation step at 95 °C for 15 seconds and an anneal-
ing/extension step at 60 °C for 1 minute. A final dissociation curve was generated to verify that a single product 
was amplified. Reactions in the absence of template and in the absence of enzyme were also included as negative 
controls. A complete data set, including gene information and experimentally obtained Ct values, is presented 
in Table S2. The RT-qPCR raw data were analyzed using the PCR Array Data analysis template (SABiosciences) 
and software available online at the SABiosciences website: www.sabiosciences.com/pcr/arrayanalysis.php, which 
provides a statistical analysis of data. Genes presenting amplification Ct values > 35 in both untreated and treated 
cells were discarded. Relative expression values of the different genes were calculated from the threshold cycle 
(Ct) following the DDCt method using ACTB, B2M, GAPDH, HPRT1 and RPLP0 as reference genes.
Xenograft experiments. Female NOD/SCID mice of 5–6 weeks old (Janvier Labs, St Berthevin, France) 
were inoculated subcutaneously (s.c.) with 5 × 105, 5 × 104 or 1 × 104 T5H-FC#1 / MSC-5H-FC cells or 400 
T-5H-O cells mixed 1:1 with BD Matrigel Matrix High Concentration (BD Biosciences, Erembodegem, Belgium) 
previously diluted 1:1 in culture medium. Tumor size was measured with a caliper 2–3 times a week and tumor 
volume was determined using the equation (D × d2)/6 × 3.14, where D is the maximum diameter, and d is the 
minimum diameter. Tumor volumes for all mice in each xenograft-treatment group were averaged to obtain the 
mean tumor volume for the corresponding group. Student’s t-test was performed to determine the statistical 
significance between control and treated groups. Animals were sacrificed when the tumors formed from tumor-
sphere cultures reached approximately 1,000 mm3. Relative tumor-initiating frequency (TIF) was calculated using 
the data obtained at the day that differences in tumor volume between tumorsphere and adherent groups became 
statistically significant (day 14 after inoculation) using the ELDA software53. Upon removal, tumor samples were 
fixed in formol, embedded in paraffin, cut into 4-μ m sections, and stained with hematoxylin and eosin (H&E) and 
anti-ALDH1A1 [(ab105920), 1:400 dilution] from Abcam (Cambridge, UK) as previously described54. All experi-
mental protocols were carried out in accordance with the institutional guidelines of the University of Oviedo and 
were approved by the Animal Research Ethical Committee of the University of Oviedo prior to the study.
Western blot. Whole cell protein extraction and western blot analysis were performed as previously 
described55. The antibodies used in Western blot analysis were as follows: anti-ALDH1A1 [(ab105920), 1:1,000 
dilution] from Abcam (Cambridge, UK); anti-ALDH1A3 [(AP7847a), 1:50 dilution] from Abgent (San Diego, 
CA); anti-SOX2 [(PA1-094), 1:1,000 dilution] from Thermo Fisher (Waltham, MA); and anti-β -Actin [(A-1978), 
1:20,000 dilution] from Sigma.
Immunofluorescence staining. For the 2-D immunofluorescence staining experiments, adherent and 
tumorsphere cultures were left to attach to glass coverslips, fixed with 4% formaldehyde (Sigma) for 15 min 
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at room temperature (RT) and permeabilized in PBS containing 0.2% triton X-100 (Sigma) for 5 min at 4 °C. 
Cells were then blocked with PBS containing 1% BSA and 0.05% Tween 20 (PBT) for 5 min at RT and incubated 
with 1:200 diluted mouse monoclonal anti-ALDH1A1 (ab105920 from Abcam,) or 1:250 diluted rabbit mon-
oclonal anti-SOX2 (PA1-094 from Thermo Fisher) for 24 hours, washed 3 times with PBS and incubated with 
1:300 anti-mouse alexa fluor 555 (A-21422 from Thermo Fisher) or 1:300 anti-rabbit alexa fluor 555 (A-21428 
from Thermo Fisher) for 1 hour in the dark. Antibody dilutions and washes after incubations were conducted 
in PBT. Coverslips were finally mounted in Vectashield mounting medium with DAPI (Vector Laboratories Inc.; 
Burlingame, Ca).
In the 3-D staining experiments, tumorspheres cultures from GFP-positive cells were washed with 
phosphate-buffered saline (PBS) twice and fixed in 4% paraformaldehyde (Sigma) in PBS for 20 minutes. 
Tumorspheres were then washed 3 times with PBS, permeabilized in PBS plus 0.1% triton X-100 (Sigma) for 20 
minutes, washed another 5 times with PBS and incubated with the blocking solution (10% goat serum in PBS) for 
1 hour. Afterward, tumorspheres were incubated with rabbit monoclonal anti-SOX2 [1:150 dilution] and mouse 
monoclonal anti-ALDH1A1 [1:150 dilution] for 36 hours, washed 4 times with PBS plus 0.1% Tween-20 for 10 
minutes and incubated with anti-mouse alexa fluor 555 (1:300 dilution) and anti-rabbit alexa fluor 647 IgG [1:300 
dilution (ab150079 from Abcam)] for 1 hour. Finally, the slides were washed extensively with PBS, pipetted into 
a drop of ProLong® Gold Antifade Mountant medium (P36930 from Life Technologies) and deposited in μ -Slide 
8-well chambered coverslips (80826 from Ibidi; Planegg, Germany).
Confocal section and projection images collected with identical exposure times were obtained using an 
Ultra-Spectral TCS-SP2-AOBS confocal microscope (Leica, Wetzlar, Germany). Quantification of positive nuclei 
(SOX2) or nuclei + cytoplasm (ALDH1A1) in 2D experiments were performed in 10-12 randomly selected fields 
using Confocal Uniovi Image J software 1.5.1 (University of Oviedo, Spain; http://www.sct.uniovi.es/confocal-
uniovi) based in the Image J software (National Institute of Health, Bethesda, MD).
Aldefluor assay. ALDH activity was determined using the activated AldefluorTM reagent, a fluorescent 
non-toxic substrate for ALDH1 able to freely diffuse into intact and viable cells (Stem Cells Technologies, 
Grenoble, France). 1 × 106 cells were suspended in 1 ml of Aldefluor assay buffer containing the ALDH1 substrate 
(Bodipy-Aminoacetaldehyde) and incubated for 45 min at 37 °C. As a reference control, the cells were suspended 
in buffer containing the substrate in the presence of diethylaminobenzaldehyde (DEAB; 20 μ M for the exper-
iments described in Fig. 4 and 10 μ M for the rest of the experiments), a specific ALDH1 enzyme inhibitor. Of 
note, the lower concentration of DEAB failed to fully inhibit high ALDEFLUOR activities (e.g., those observed in 
tumorsphere cultures of T-5H-O cells) as previously reported48. In any case, gates were established to include less 
than 1% positive cells in the DEAB controls of the condition displaying less ALDEFLUOR activity in adherent 
or tumorsphere cultures and were maintained in all conditions. Cells were incubated with 0.5 μ g/ml propidium 
iodide for 15 min, and cells positive for this staining (dead cells) were excluded from the analysis (Figure S7). The 
brightly fluorescent ALDH1-expressing cells (ALDH1high) were detected and sorted using the green fluorescence 
channel (520–540 nm) of a MoFlo XDP flow cytometry (Beckman Coulter, Brea, CA).
siRNA transfection. ALDH1A1 (J-008722-06-0002) and ALDH1A3 (J-009082-07-0002) On-Target plus siRNAs 
and siGenome RiSC-Free control siRNA (D-001220-01) were from Dharmacon (Lafayette, CO). SiRNA sequences 
were as follows: ALDH1A1: GAACAGUGUGGGUGAAUUG; ALDH1A3: UGAAUACGCUUUGGCCGAA. 
Cells were transfected with 200 pmol/ml siRNAs using Lipofectamine 3000 (Life Technologies) according to the 
manufacturer’s instructions. 48 hours after transfection, cells were collected and analyzed56.
Soft agar colony formation assay. A soft agar colony formation assay was carried out using the 
CytoSelectTM 96-Well Cell Transformation Assay Kit (Cell Biolabs Inc, San Francisco, CA) as described57. 
Quantification of anchorage-independent cell growth was performed after agar layer solubilization and cell 
recovering according to the manufacturer’s instructions. Cell viability was analyzed using the Cell Proliferation 
Reagent WST-1 (Roche, Mannheim, Germany). Briefly, recovered cells were plated in 24-well plates, left to attach 
to the plastic substrate (4–6 hours) and incubated for 1 hour at 37 °C with 18 μ l/ml of WST-1 reagent. The color 
change produced by the cleavage of the WST-1 reagent by mitochondrial dehydrogenases was measured by read-
ing the absorbance at 440 nm with the use of a Synergy HT plate reader (BioTek, Winooski, VT). The surviving 
fraction at each treatment was calculated as a percentage of untreated cells. Two independent experiments were 
performed in triplicate.
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